The Council Tax Reduction (Scotland) Amendment (No. 3) Regulations 2024

Amendment of the Council Tax Reduction (State Pension Credit) (Scotland) Regulations 2012

2.—(1) The Council Tax Reduction (State Pension Credit) (Scotland) Regulations 2012(1) are amended in accordance with paragraphs (2) to (6).

(2) In regulation 2(1) (interpretation)—

(a) omit the definitions of “the Caxton Foundation”, “the Eileen Trust”, “the Fund”, “MFET Limited”, “the Macfarlane Trust”, “the Macfarlane (Special Payments) Trust”, “the Macfarlane (Special Payments) (No. 2) Trust”, “the Skipton Fund” and “the Trusts”,

(b) for the definition of “infected blood payment scheme” substitute—

““infected blood payment scheme” means a scheme established by, or with the approval of, the Scottish Ministers, the Secretary of State, the Minister for the Cabinet Office, the Welsh Ministers or the Department of Health in Northern Ireland, or a trust established with funds provided by the Secretary of State, for making compensation, support or ex gratia payments to or in respect of persons who—

(a)

have been infected as a result of being treated with blood, blood products or tissue,

(b)

have been infected as a result of another person being treated with blood, blood products or tissue, or

(c)

have been affected by another person being infected as described in sub-paragraph (a) or (b);”.

(3) In regulation 48(9) (non-dependant deductions)—

(a) in sub-paragraph (b) omit “the Trusts, the Fund, the Eileen Trust, MFET Limited, the Skipton Fund, the Caxton Foundation, another infected blood payment scheme,”,

(b) at the end of sub-paragraph (j) omit “and”,

(c) at the end of sub-paragraph (k) insert—

“;

(l) any payment made under or by an infected blood payment scheme; and

(m) any payment made from the estate of a deceased person where—

(i) the payment derives from a payment made under or by an infected blood payment scheme, and

(ii) the payment it derives from was made to the estate of the deceased person as a result of that person having been infected through treatment with blood, blood products, or tissue, or through another person being so infected”.

(4) In regulation 66(3) (evidence and information)—

(a) in sub-paragraph (a) omit “the Trusts, the Fund, the Eileen Trust, MFET Limited, the Skipton Fund, the Caxton Foundation, another infected blood payment scheme,”,

(b) at the end of sub-paragraph (b) omit “and”,

(c) in sub-paragraph (c)—

(i) for “48(9)(b) or (c)” substitute “48(9)(b) to (m)”,

(ii) for “2(b) or (c) of Schedule 5” substitute “2(b) to (l) of schedule 5”,

(d) at the end of sub-paragraph (c) insert—

“;

(d) a payment made under or by an infected blood scheme; and

(e) any payment made from the estate of a deceased person where—

(i) the payment derives from a payment made under or by an infected blood payment scheme, and

(ii) the payment it derives from was made to the estate of the deceased person as a result of that person having been infected through treatment with blood, blood products or tissue, or through another person being so infected”.

(5) In paragraph 16 of schedule 4 (capital disregards)—

(a) in sub-paragraph (1)(a) omit “the Trusts, the Fund, the Eileen Trust, MFET Limited, the Skipton Fund, the Caxton Foundation, another infected blood payment scheme,”,

(b) after sub-paragraph (1E)(2) insert—

“(1F) Any payment made under or by an infected blood payment scheme.

(1G) Any payment made from the estate of a deceased person where—

(i) the payment derives from a payment made under or by an infected blood payment scheme, and

(ii) the payment it derives from was made to the estate of the deceased person as a result of that person having been infected through treatment with blood, blood products or tissue, or through another person being so infected.”,

(c) in sub-paragraphs (2) and (3), omit “who is suffering, or who suffered, from haemophilia or”,

(d) in sub-paragraph (3), at the end, for “the person who is suffering from haemophilia or who is a qualifying person” substitute “the qualifying person”,

(e) in sub-paragraph (4) omit “who is suffering from haemophilia or”,

(f) in sub-paragraph (5) omit “who suffered from haemophilia or”,

(g) in sub-paragraphs (2) to (5) after “any of the Trusts” insert “or an infected blood payment scheme”,

(h) in sub-paragraph (6) after “the Trusts” insert “, an infected blood payment scheme”,

(i) in sub-paragraph (7)—

(i) in head (a) for “the Fund, the Eileen Trust, MFET Limited, the Skipton Fund, the Caxton Foundation, another infected blood scheme,” substitute “, an infected blood payment scheme”,

(j) in sub-paragraph (8) for “For the purposes of sub-paragraphs (2) to (6), any reference to the Trusts is to be construed as including a reference to the Fund, the Eileen Trust, MFET Limited, the Skipton Fund, the Caxton Foundation, any other infected blood payment scheme,” substitute “For the purposes of sub-paragraphs (2) to (6), any reference to the Trusts is to be construed as meaning”.

(6) In paragraph 2 of schedule 5 (amount of alternative maximum council tax reduction)—

(a) in sub-paragraph (b) omit “the Trusts, the Fund, the Eileen Trust, MFET Limited, the Skipton Fund, the Caxton Foundation, another infected blood payment scheme,”,

(b) at the end of sub-paragraph (b) omit “and”,

(c) after sub-paragraph (c) insert—

“(d) any Grenfell Tower payment;

(e) any Post Office compensation payment;

(f) any payment or interest on a payment made under the Windrush Compensation (Expenditure) Act 2020;

(g) a vaccine damage payment made in any of the circumstances described in paragraph 16(1D) of schedule 4(3);

(h) any payment made under the Victims of Overseas Terrorism Compensation Scheme;

(i) any redress payment made under Part 4 of the Redress for Survivors (Historical Child Abuse in Care) (Scotland) Act 2021(4);

(j) any ex gratia payment made at the discretion of the Scottish Ministers from the Advance Payment Scheme within the meaning of section 42(7) of the Redress for Survivors (Historical Abuse in Care) (Scotland) Act 2021;

(k) any payment made under or by an infected blood payment scheme; and

(l) any payment made from the estate of a deceased person where—

(i) the payment derives from a payment made under or by an infected blood payment scheme, and

(ii) the payment it derives from was made to the estate of the deceased person as a result of that person having been infected through treatment with blood, blood products or tissue or through another person being so infected”.

(1)

S.S.I. 2012/319, which was relevantly amended by S.S.I. 2013/49, S.S.I. 2013/287, S.S.I. 2016/81, S.S.I. 2017/41, S.S.I. 2017/326, S.S.I. 2021/249. S.S.I. 2023/38, S.S.I. 2023/149, S.S.I. 2023/268 and S.S.I. 2024/35.

(2)

Sub-paragraph (1E) was inserted into paragraph 16 by S.S.I. 2024/35.

(3)

Sub-paragraph (1D) was inserted into paragraph 16 by S.S.I. 2023/268.

(4)

2021 asp 15.